Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.4852W HIGH $16.93
Volume
18.96 K
Value Traded
177.40 K
Short % Float
2.7%
Days to Cover
4.3
-9.28%Week
-0.74%1 Month
-16.76%3 Month
-6.97%6 Month
-90.97%5 Year
-90.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
47.95 M
EPS (TTM)
-2.15
P/E Ratio
-
Ent. Value
40.48 M
Total Shares
5.13 M
Float Shares
2.04 M
Insiders
60.10%
Institutions
3.99%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
INKT Catalyst Timeline
Dated clinical, regulatory and corporate events for MiNK Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MiNK Therapeutics, Inc.
238Total events
16Upcoming
26Tier-1 (high impact)
2021 to 2030Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationagenT-797Presentation
Poster #270 on agenT-797 in human organoid model of CPI-refractory CRC liver metastases at SITC 2026
colorectal cancer liver metastasessource ↗
●Poster PresentationPresentation
Poster #177 on native and engineered iNKT cells eliminating senescent tumor cells and fibroblasts at SITC 2026
senescent tumor cells and fibroblastssource ↗
▲Preclinical PoCMiNK-215Preclinical
SITC 2026 preclinical data: agenT-797 and MiNK-215 act as living senolytics
senescence / fibrotic lung diseasesource ↗
▲Preclinical PoCagenT-797Preclinical
SITC 2026 preclinical data: agenT-797 unlocked tumor-cell killing with BOT/BAL in MSS CRC organoids
MSS colorectal cancer with liver metastasessource ↗
▲Partnership / LicenseagenT-797Corporate
MiNK's agenT-797 iNKT platform selected as therapeutic cell system within ARPA-H-funded RAB team
▲Grant / FundingagenT-797Corporate
agenT-797 selected for Draper-led ARPA-H BoSS team (up to $87M program-wide funding)
▲Oral PresentationagenT-797Presentation
Initial Day 28 observations presented at MHSRS
Acute Lung Injury and ARDSsource ↗
▲Other Regulator MilestoneagenT-797Ex-US Regulatory
Paid named-patient access program launched in Brazil
Acute Lung Injury and ARDSsource ↗
◆Oral PresentationagenT-797Presentation
Presentation of early observations from Phase 2 trial at MHSRS
severe hypoxemic pneumoniasource ↗
◆Enrollment UpdateagenT-797Trial
Enrollment ongoing in Lviv with U.S. sites opening
severe hypoxemic pneumoniasource ↗
▲Poster PresentationagenT-797Presentation
Initial Day 28 observations from first agenT-797-treated ARDS patients presented at Military Health System Research Symposium
ARDSsource ↗
▲Enrollment UpdateagenT-797Trial
Randomized Phase 2 ARDS trial (C-1300-02) continued enrolling during Q3 2026
acute respiratory distress syndrome (ARDS) / acute lung injury with moderate-to-severe hypoxemic respiratory failuresource ↗
▲Product LaunchagenT-797Post-Market
First pre-commercial product revenue from agenT-797 named-patient access program
serious unmet medical need (named-patient access)source ↗
▲First Patient DosedagenT-797Trial
First patient dosed in randomized Phase 2 trial of agenT-797 in acute lung injury
acute lung injury and critical illnesssource ↗
◆Poster PresentationagenT-797Presentation
Poster presentation at ATS 2026 on agenT-797 and N-803 combination immunotherapy
Coccidioides immitis infection with concurrent ARDSsource ↗
◆PublicationagenT-797Presentation
Publication in Clinical Immunology Communications on agenT-797 and N-803 combination
Coccidioides immitis infection with concurrent ARDSsource ↗
▲Trial InitiationagenT-797Trial
Initiation of randomized Phase 2 trial of agenT-797 in severe acute lung injury
severe acute lung injury and critical illnesssource ↗
◆Oral PresentationagenT-797Presentation
ATS 2026 presentation on agenT-797 combination immunotherapy for coccidioidomycosis
unresolving Coccidioides immitis infectionsource ↗
▲Trial InitiationagenT-797Trial
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and critical illness
severe acute lung injury and critical illnesssource ↗
▲Trial InitiationagenT-797Trial
Initiation of randomized Phase 2 trial of agenT-797 in acute lung injury
acute lung injury and hypoxemic respiratory failuresource ↗
◆Poster PresentationagenT-797Presentation
Poster 3371: Context-Dependent Immune Reprogramming in Cancer and ARDS at ASGCT 2026
solid tumors; acute respiratory distress syndrome (ARDS)source ↗
◆Poster PresentationagenT-797Presentation
Poster presentation at ASGCT 2026 on agenT-797 adaptive immune modulation in cancer and ARDS
cancer and ARDSsource ↗
▲First Patient DosedagenT-797Trial
First patient dosed in randomized Phase 2 trial C-1300-02
Acute Lung Injury and ARDSsource ↗
▲Other Regulator MilestoneagenT-797Ex-US Regulatory
Ministry of Health authorization in Ukraine received
Acute Lung Injury and ARDSsource ↗
▲Oral PresentationagenT-797Presentation
Data presented at ATS 2026 and published in Clinical Immunology Communications
Coccidioides infectionsource ↗
◆Poster PresentationagenT-797Presentation
Phase II study of agenT-797, botensilimab and balstilimab in PD-1 refractory GEC at AACR 2026
PD-1 refractory gastroesophageal cancersource ↗
◆Oral PresentationagenT-797Presentation
Oral presentation of Phase II data for agenT-797 + botensilimab + balstilimab at AACR 2026
PD-1 refractory gastroesophageal adenocarcinomasource ↗
▲Topline ReadoutagenT-797Clinical Data
Phase II topline data: DCR 77%, PFS HR 0.19, OS 9.5 vs 5.2 months
PD-1 refractory gastroesophageal adenocarcinomasource ↗
▼Primary Endpoint MissedagenT-797Clinical Data
Phase II study did not meet primary endpoint of ORR
PD-1 refractory gastroesophageal adenocarcinomasource ↗
◆Topline ReadoutagenT-797Clinical Data
Preliminary data expected from Phase 2 trial of agenT-797
acute lung injury and hypoxemic respiratory failuresource ↗
◆Trial InitiationagenT-797Trial
Phase 2 trial initiation for hypoxemic pneumonia/ARDS
hypoxemic pneumonia/ARDSsource ↗
●ATM ProgramCorporate
At-the-market sales agreement executed and additional $3.0 million raised since year end
▲Partnership / LicenseCorporate
Collaboration with C-Further to advance PRAME-targeted iNKT cell therapy
pediatric cancerssource ↗
●Poster PresentationPresentation
Poster presentation of translational data on iNKT cell depletion in IPF at Keystone Symposia
idiopathic pulmonary fibrosissource ↗
◆Trial InitiationagenT-797Trial
Phase 1 investigator-sponsored trial of agenT-797 in GvHD prevention to initiate
prevention of graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantationsource ↗
▲Partnership / LicenseCorporate
Collaboration with C-Further for PRAME-targeted TCR-engineered iNKT cell therapy
pediatric cancerssource ↗
▲First Patient DosedagenT-797Trial
First patient dosed in Phase 2 trial
severe hypoxemic pneumoniasource ↗
▲Preclinical PoCMiNK-215Preclinical
Publication of preclinical data for MiNK-215 in Cancer Immunology Research
solid tumorssource ↗
▲Oral PresentationagenT-797Presentation
Updated clinical data presented at SITC 2025 showing durable remissions
solid tumorssource ↗
▲PublicationagenT-797Presentation
Publications in Oncogene and Frontiers in Immunology validating agenT-797 mechanism
oncology and inflammatory diseasessource ↗
Past FDA Catalysts and PDUFA Decisions
How INKT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-07 | agenT-797 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 89%
Micro Cap(rank 644 of 724)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every INKT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| agenT-797 | checkpoint inhibitor–resistant colorectal cancer liver metastases | Phase 2 | 2026-10-02 | enables tumor-cell killing in a human relevant model of checkpoint inhibitor · resistant colorectal cancer liver metastasesRead More | MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Buell JenniferDirector, Officer (Chief Executive Officer) | Sell | -6,938 74,195 held | $10.56 | 10/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INKT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0 % | 682.22 K | 324.87 K |
Ownership Trends
INKT Short Interest
Shares sold short, counted twice a month.
2.7%
Short % of Float
of tradable shares sold short
55.1K
Shares Sold Short
+15.3% vs prior count
4.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
12.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INKT ranks across every disease it competes in
Competitive Position is a premium feature
See how INKT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINKT News
INKT▼ -2%today
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
MiNK Therapeutics reported its Q3 2026 results, marking the first revenue from agenT-797 through named-patient access. The company is advancing its randomized Phase 2 trial for ARDS, with U.S. dosing anticipated by year-end. Additionally, MiNK was selected for an ARPA-H program aimed at developing room-temperature deployable cell therapies.
Read more →INKT▲ +5.4%on this newsshared move
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
MiNK Therapeutics presented preclinical data at SITC 2026. The studies showed agenT-797 restored tumor killing in resistant colorectal cancer models. The data also demonstrated elimination of senescent cells by iNKT therapies. These findings support ongoing Phase 2 trials in cancer and respiratory disease.
Read more →INKTMiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
MiNK Therapeutics will report its Q3 2026 financial results on November 11, 2026. The company will also provide updates on the randomized clinical development of agenT-797, its lead iNKT cell therapy. Key priorities include advancing trials in acute lung injury and expanding iNKT therapies for treatment-resistant cancers.
Read more →INKTMiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
MiNK Therapeutics announced two poster presentations at the SITC 2026 Annual Meeting, focusing on their innovative therapies for treatment-resistant colorectal cancer and senescent tumor cells. The presentations highlight the efficacy of agenT-797 in overcoming checkpoint inhibitor resistance and the potential of engineered iNKT cells in targeting tumor microenvironments. These findings support ongoing clinical trials and emphasize MiNK's commitment to advancing cancer treatment.
Read more →INKTMiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
MiNK Therapeutics has been selected for the ARPA-H-funded BioStabilization Systems (BoSS) program, which aims to enable room-temperature storage of living cell therapies. The initiative, backed by up to $87 million, seeks to reduce reliance on cold-chain logistics, potentially increasing accessibility to advanced biologic medicines. MiNK's agenT-797 iNKT platform will play a key role in this transformative project.
Read more →INKTMiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
MiNK Therapeutics reported positive initial results from its randomized Phase 2 trial of agenT-797 for acute lung injury, with patients showing improved oxygenation and recovery by Day 28. The company has also initiated a paid international named-patient access program to expand availability of the treatment. Financial results indicate a reduced net loss compared to the previous year.
Read more →INKT▼ -8.1%on this news
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
MiNK Therapeutics presented early observations from its Phase 2 trial of agenT-797 at the 2026 Military Health System Research Symposium. The initial data showed that patients treated with agenT-797 experienced improved oxygenation and infection control by Day 28, with no major adverse events reported. The trial aims to evaluate the therapy's effectiveness in severe hypoxemic pneumonia, with further data expected in early 2027.
Read more →INKT▼ -6%on this newsshared move
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
MiNK Therapeutics will report its Q2 2026 financial results on August 13, 2026, and will host a conference call to discuss these results and provide updates on its iNKT cell therapy, agenT-797, for acute lung injury. The call will include new clinical data and information about a named-patient program. MiNK is focused on developing innovative immune therapies.
Read more →INKT▲ +6.7%on this news
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
MiNK Therapeutics has announced its virtual Annual Shareholders Meeting scheduled for June 17, 2026, at 9:30 a.m. ET. Shareholders can register starting at 9:15 a.m. ET, and guests can listen in without a control number. The company is known for its pioneering work in allogeneic iNKT cell therapies aimed at treating immune dysfunction.
Read more →INKT▲ +19.8%on this news
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics has initiated a randomized Phase 2 trial for agenT-797 in patients with acute lung injury and critical illness. The first patient was dosed at a medical facility in Ukraine shortly after receiving approval from the Ministry of Health. This trial aims to evaluate the efficacy of agenT-797 compared to a placebo, focusing on critical ICU outcomes. Preliminary data is expected in the second half of 2026.
Read more →INKTMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
MiNK Therapeutics announced positive new clinical findings on its allogeneic iNKT cell therapy, agenT-797, presented at ATS 2026 and published in Clinical Immunology Communications. The data indicated significant immune restoration and pathogen suppression in a critically ill patient with multiple severe infections. Following treatment with agenT-797 and the IL-15 superagonist N-803, researchers noted reduced inflammatory signaling and activation of tissue repair pathways. However, the case was complicated by cardiac-related issues leading to the patient's transition to comfort care.
Read more →INKTMiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
MiNK Therapeutics has initiated a randomized Phase 2 trial for its iNKT cell therapy, agenT-797, targeting severe acute lung injury and respiratory distress. The trial aims to evaluate the therapy's efficacy alongside standard care, with preliminary results expected in late 2026. The company also reported financial results and highlighted collaborations that support its platform expansion. Upcoming presentations at major conferences will further discuss the therapy's potential in various clinical settings.
Read more →INKTMiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics has announced the initiation of a randomized Phase 2 trial for its agenT-797 therapeutic, targeting acute lung injury in partnership with the First Lviv Territorial Medical Union in Ukraine. This trial is designed to evaluate the efficacy of donor-derived iNKT cells added to standard care versus placebo in critically ill patients. The collaboration aims to generate clinically meaningful data that could support future treatments for patients suffering from severe immune dysfunction. Preliminary results are anticipated in the second half of 2026, aiming to improve outcomes in high-acuity critical care settings.
Read more →INKTMiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
MiNK Therapeutics presented data at ASGCT 2026 showing that their iNKT cell therapy, agenT-797, induces context-dependent immune responses in cancer and ARDS patients. The therapy demonstrated significant clinical activity, including complete remission in solid tumors and improved survival in ARDS. The findings support a randomized Phase 2 trial for acute lung injury, with preliminary data expected in 2026.
Read more →INKTMiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
MiNK Therapeutics plans to report its first quarter 2026 financial results on May 15, 2026. The company will also provide updates on its iNKT cell therapy programs, including the lead candidate agenT-797. Recent advancements and collaborations, particularly in pediatric cancer therapies, will be discussed during the conference call.
Read more →INKTMiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
MiNK Therapeutics announced promising Phase II data for agenT-797 in combination with botensilimab and balstilimab, showing a 77% disease control rate in patients with PD-1 refractory gastroesophageal cancer. The study highlighted long-term survival beyond 20 months for some patients and significant improvements in progression-free survival associated with the use of an induction therapy strategy. Although the trial did not meet its primary endpoint regarding overall response rate, the findings provide valuable insights into the treatment's potential. Safety profiles were consistent with existing therapies, and further analysis is ongoing to optimize treatment sequencing and identify suitable biomarkers.
Read more →INKT▲ +7%on this news
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
MiNK Therapeutics announced that data from a Phase II trial of agenT-797, in combination with botensilimab and balstilimab, will be presented at the AACR Annual Meeting 2026. This study focuses on patients with PD-1 refractory gastroesophageal cancer, aiming to explore immune modulation and treatment sequencing. The findings could inform future strategies for managing this challenging cancer type.
Read more →INKTMiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
MiNK Therapeutics announced that their investigational iNKT cell therapy, agenT-797, will be presented at the ASGCT Annual Meeting in May 2026. The abstract highlights the therapy's adaptive immune modulation capabilities in cancer and acute respiratory distress syndrome (ARDS). The presentation will be led by Dr. Terese C. Hammond, showcasing the potential of agenT-797 in clinical applications.
Read more →INKTMiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
MiNK Therapeutics has announced that its abstract on the investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026. The abstract discusses a novel combination immunotherapy approach for treating unresolving Coccidioides immitis infections. The presentation will take place on May 20, 2026, in Orlando, Florida.
Read more →INKTMiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
MiNK Therapeutics reported its Q4 and full-year 2025 results, highlighting advancements in its Phase 2 programs, including a trial for ARDS set to begin in 1H 2026. The company secured significant non-dilutive funding and is preparing for multiple clinical catalysts in 2026. Despite a net loss increase, the company is optimistic about its future prospects.
Read more →About MiNK Therapeutics, Inc.
Headquarters149 FIFTH AVENUE, NEW YORK, NY, 10010
BIOPHARMAWATCH ELITE
Trade the next INKT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime